Homogeneity in immune features between colorectal liver metastases better identifies patients with good prognosis compared to pathological response to preoperative chemotherapy.
Colorectal liver metastasis
immune score
prognostic biomarker
tumor heterogeneity
tumor infiltrating lymphocytes
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
19
9
2023
pubmed:
18
9
2023
entrez:
18
9
2023
Statut:
epublish
Résumé
In colorectal cancer liver metastases (CRLM), the density of tumor-infiltrating lymphocytes, the expression of class I major histocompatibility complex (MHC-I), and the pathological response to preoperative chemotherapy have been associated with oncological outcomes after complete resection. However, the prognostic significance of the heterogeneity of these features in patients with multiple CRLMs remains under investigation. We used a tissue microarray of 220 mismatch repair-gene proficient CRLMs resected in 97 patients followed prospectively to quantify CD3
Identifiants
pubmed: 37720689
doi: 10.1080/2162402X.2023.2253642
pii: 2253642
pmc: PMC10503458
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2253642Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
Outside the submitted work, S.T. has received consultant fees from Bristol Myers Squibb and Turnstone Biologics, speaking fees from Celgene and Astra Zeneca, and has research funding from Iovance Biotherapeutics and Turnstone Biologics.
Références
NPJ Genom Med. 2021 Jul 14;6(1):59
pubmed: 34262039
Oncoimmunology. 2013 Apr 1;2(4):e24116
pubmed: 23734335
PLoS Genet. 2016 Jul 29;12(7):e1006225
pubmed: 27472274
Front Immunol. 2020 Mar 06;11:369
pubmed: 32210966
Ann Oncol. 2007 Feb;18(2):299-304
pubmed: 17060484
Oncogenesis. 2020 Jul 9;9(7):66
pubmed: 32647253
Mol Oncol. 2021 Apr;15(4):830-845
pubmed: 33325154
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3
pubmed: 30537506
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Sci Transl Med. 2016 Feb 24;8(327):327ra26
pubmed: 26912905
J Clin Oncol. 2007 Oct 10;25(29):4575-80
pubmed: 17925551
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Oncoimmunology. 2012 Aug 1;1(5):593-599
pubmed: 22934251
Ann Surg. 2019 Jan;269(1):120-126
pubmed: 28549012
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Oncotarget. 2018 Sep 28;9(76):34279-34288
pubmed: 30344942
J Clin Oncol. 2008 Nov 20;26(33):5344-51
pubmed: 18936472
J Pathol Clin Res. 2021 Jan;7(1):27-41
pubmed: 32902189
Cancer Immunol Res. 2014 Jun;2(6):530-7
pubmed: 24894090
Oncoimmunology. 2020 Apr 23;9(1):1746138
pubmed: 32363113
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Br J Cancer. 2022 May;126(9):1329-1338
pubmed: 34980880
NPJ Genom Med. 2017;2:
pubmed: 28819565
J Natl Cancer Inst. 2018 Jan 1;110(1):
pubmed: 28922789
Surg Oncol. 2018 Jun;27(2):280-288
pubmed: 29937183